Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.46 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.43 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | GGT1 | P19440 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731724 | 0.85 | LMNA (0.51) | LMNAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27132922 | 0.83 | STS (0.51) | LMNAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| Methyl Alcohol SCHEMBL28150169 | 0.83 | KDM4E (0.55) | LMNAKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL32665166 | 0.83 | ELANE (0.52) | LMNAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL26647 | 0.82 | KDM4E (0.53) | LMNAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| SCHEMBL27480641 | 0.81 | L3MBTL1 (0.69) | LMNAKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL27029738 | 0.81 | STS (0.50) | LMNAKDM4EALDH1A1SMN1; SMN2KMT2A | |
| Bromomethane SCHEMBL26113406 | 0.81 | KDM4E (0.53) | LMNAKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL29157638 | 0.81 | KDM4E (0.54) | LMNAKDM4EALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL7091675 | 0.81 | CTNNB1 (0.55) | LMNAKDM4EALDH1A1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1998003636-A9 | NOVEL ARYLSULFOTRANSFERASE | — | 1998-05-22 | — | — | WO | claimed |
| WO-1998003636-A1 | NOVEL ARYLSULFOTRANSFERASE | BIO-TECHNICAL RESOURCES (US) | 1998-01-29 | — | — | WO | claimed |
| EP-0531537-B1 | HIRUDIN ANALOGUE OR SALT THEREOF, PRODUCTION THEREOF, AND ANTICOAGULANT CONTAINING THE SAME AS ACTIVE INGREDIENT | JAPAN ENERGY CORP (JP) | 1996-09-11 | — | — | EP | claimed |
| EP-0531537-A1 | HIRUDIN ANALOGUE OR SALT THEREOF, PRODUCTION THEREOF, AND ANTICOAGULANT CONTAINING THE SAME AS ACTIVE INGREDIENT | JAPAN ENERGY CORPORATION (JP) | 1993-03-17 | — | — | EP | claimed |
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12458617-B2 | Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| US-20220202759-A1 | Pet Food Compositions Comprising Caprylic Acid and Docosahexaenoic Acid and/or Eicosapetaenoic Acid for Use in Treating Struvite Urolithiasis | HILL'S PET NUTRITION, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-20190156919-A1 | DETERMINING RELATIONSHIPS BETWEEN RISKS FOR BIOLOGICAL CONDITIONS AND DYNAMIC ANALYTES | ARIVALE, INC. (US) | 2019-05-23 | — | — | US | disclosed |
| US-10267777-B2 | Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment | METABOLON, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170089872-A1 | SMALL MOLECULE BIOCHEMICAL PROFILING OF INDIVIDUAL SUBJECTS FOR DISEASE DIAGNOSIS AND HEALTH ASSESSMENT | METABOLON, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | disclosed |
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | UNIVERSIDADE ESTADUAL PAULISTA JULIO DE MESQUITA FILHO - UNESP (BR) | 2014-02-27 | — | — | US | disclosed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | disclosed |
| US-8569335-B2 | Compounds derived from taurine, process of their preparation and pharmaceutical compositions containing these | EMS S.A. (BR) | 2013-10-29 | — | — | US | disclosed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | disclosed |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | EMS S.A. (BR) | 2011-05-19 | — | — | US | disclosed |
| WO-1998003636-A9 | NOVEL ARYLSULFOTRANSFERASE | — | 1998-05-22 | — | — | WO | disclosed |
| WO-1998003636-A1 | NOVEL ARYLSULFOTRANSFERASE | BIO-TECHNICAL RESOURCES (US) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057959-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | LMNA 3909/4885KDM4E 2862/4885ALDH1A1 97/4885 |
| US-20260034086-A1 | Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis | FPR2, FPR1, FPR3 | LMNA 1957/4885KDM4E 3964/4885ALDH1A1 2696/4885 |
| US-20110118303-A1 | NOVEL COMPOUNDS DERIVED FROM TAURINE, PROCESS OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE | TPMT, UTS2R, NSUN3 | LMNA 3909/4885KDM4E 2862/4885ALDH1A1 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.